Artelo Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity (Tables)

Equity (Tables)

9 Months Ended

May 31, 2020

Equity [Abstract]

Schedule of activity warrants outstanding

						Weighted				Weighted
		Number of				Average				Average
		shares				Exercise Price				Life (years)
Outstanding, August 31, 2019			2,334,937			$	8.12				4.31
Granted			—				—				—
Forfeited			—				—				—
Exercised			—				—				—
Outstanding, May 31, 2020			2,334,937			$	8.12				3.55

Schedule of stock options assumptions

		Nine Months Ended				Year Ended
		May 31,				August 31,
		2020				2019
Expected term		4.34 - 5 years				5 years
Expected average volatility			155	%			158	%
Expected dividend yield			—				—
Risk-free interest rate		1.66% - 1.67		%		1.40 - 1.78		%

Schedule of stock option activity

		Options Outstanding
		Number of				Weighted Average				Weighted Average
		Options				Exercise Price				Remaining life
										(years)
Outstanding, August 31, 2019			234,000			$	3.88			$	9.78
Granted			74,000				2.48				10.00
Exercised			—				—				—
Forfeited/canceled			(26,166	)		$	3.31			$	9.10
Outstanding, May 31, 2020			281,834			$	3.57			$	9.15

Schedule of exercisable stock options outstanding

Options Outstanding												Options Exercisable
Number				Weighted Average				Weighted				Number				Weighted
of				Remaining				Average				of				Average
Options				Contractual life (in years)				Exercise Price				Shares				Exercise Price
	46,084				8.22			$	10.80				30,244			$	10.80
	2,500				9.14			$	3.12				2,500			$	3.12
	159,250				9.25			$	1.99				98,317			$	1.99
	50,000				9.52			$	2.65				6,250			$	2.65
	24,000				9.54			$	2.12				2,500			$	2.12
	281,834				9.15				3.57				139,811				3.95